Login to Your Account



Seagen partnerships progress, bringing a potential second approval closer

By Michael Fitzhugh
Staff Writer

Tuesday, October 10, 2017

Seattle Genetics Inc. shared progress on two key development programs Tuesday, dosing the first patient in a registrational phase II study of enfortumab vedotin for locally advanced or metastatic urothelial cancer and initiating a new phase II study of tisotumab vedotin in patients with advanced cervical cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription